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Abstract 
The synthesis and biochemical activities of novel water-soluble β-lactam analogues of 
combretastatin A-4 are described. The first series of compounds investigated, β-lactam 
phosphate esters 7a, 8a and 9a, exhibited potent antiproliferative activity and caused 
microtubule disruption in human breast carcinoma-derived MCF-7 cells. They did not 
inhibit tubulin polymerisation in vitro, indicating that biotransformation was necessary 
for their antiproliferative and tubulin binding effects in MCF-7 cells. The second series of 
compounds, β-lactam amino acid amides (including 10k and 11l) displayed potent 
antiproliferative activity in MCF-7 cells, disrupted microtubules in MCF-7 cells and also 
inhibited the polymerisation of tubulin in vitro. This indicates that the β-lactam amides 
did not require metabolic activation to have antiproliferative effects, in contrast to the 
phosphate series. Both series of compounds caused mitotic catastrophe and apoptosis in 
MCF-7 cells. Molecular modelling studies indicated potential binding conformations for 
the β-lactam amino acid amides 10k and 11l in the colchicine-binding site of tubulin. Due 
to their aqueous solubility and potent biochemical effects, these compounds are 
promising candidates for further development as microtubule-disrupting agents. 
Keywords 
Antiproliferative; beta-lactam; combretastatin A-4; prodrug; solubility; tubulin. 
Abbreviations 
CA-1  Combretastatin A-1 
CA-4  Combretastatin A-4 
DIPEA Diisopropylethylamine 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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NAC  N-Acetylcolchicine 
PBS  Phosphate buffered saline 
 
1. Introduction 
Solubility limitations to oral drug delivery are frequently encountered in drug 
development [1, 2]. There are many formulation and drug design strategies that can be 
used to overcome solubility issues, such as use of surfactants and co-solvents. Design of 
soluble prodrugs is a routine technique used to overcome solubility problems [3]. We 
have recently reported a series of β-lactams with extremely potent antiproliferative 
effects [4, 5]. These compounds are amongst the most potent analogues of combretastatin 
A-4 reported to date, but their further development is limited by lack of aqueous 
solubility. Hence, we designed phosphate- and amino acid-containing derivatives of the 
β-lactams to improve their pharmacokinetic profile. 
1.1 Phosphate ester prodrugs 
Phosphate ester prodrugs are useful for phenolic and amino-containing poorly water-
soluble drugs to enhance their aqueous solubility. Phosphate prodrugs display excellent 
chemical stability and rapid bioconversion in vivo to the parent drug by phosphatases 
present in the intestinal brush border or in the liver [1]. Examples of commercially 
available phosphate prodrugs include the anti-epileptic fosphenytoin [3], the antiviral 
fosamprenavir and the steroid prednisolone phosphate [1]. Phosphate prodrugs of tubulin-
binding agents are known, for example those of N-acetylcolchicine (1), combretastatin A-
4 (2), combretastatin A-1 (3) and phenstatin (4, Figure 1). Phosphate prodrug 1a (Figure 
1) demonstrated increased water-solubility and delayed metabolism compared to 1. 
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Analogue 1a showed comparative effects to 1 in vivo but did not inhibit in vitro 
polymerisation of tubulin, indicating that phosphate compound 1a itself is inactive and 
requires enzymatic activation in vivo [6]. Prodrug 1a was in clinical trials in the United 
States for the treatment of metastatic renal cell carcinoma, but these were halted due to 
cardiotoxicity problems [7]. 
 
Combretastatin prodrugs have been extensively investigated, including phosphate 
prodrugs of combretastatin A-4 (CA-4, 2, Figure 1) [8], combretastatin A-1 (CA-1, 3, 
Figure 1) [9], combretastatin B-1 [9], stilstatins 1 and 2 [10] and iodocombretastatins 
[11]. Due to the sparing aqueous solubility of 2, initial formulation attempts were 
unsuccessful [8]. The phosphate ester prodrug CA-4P (2a, Figure 1) had excellent water 
solubility, good stability and good cell growth inhibitory activity, with a mean panel GI50 
of 6.89 nM (compared to 6.61 nM for 2) in the NCI screen [8]. Prodrug 2a is rapidly 
dephosphorylated to 2 in vivo with a half-life of a few minutes [12]. It is under evaluation 
in phase 3 trials for treatment of anaplastic thyroid cancer and in phase 2 trials for non-
small cell lung cancer and platinum-resistant ovarian cancer [13]. Phenstatin (4, Figure 1) 
is a benzophenone-type compound structurally similar to 2 with potent antiproliferative 
and tubulin-binding activity but poor aqueous solubility. A phosphate prodrug (4a, Figure 
1) was prepared to improve water-solubility and had equivalent antiproliferative activity 
compared to the parent compound 4 [14].  
1.2 Amino Acid Prodrugs 
Like phosphate prodrugs, amino acid prodrugs also confer the advantage of increased 
aqueous solubility to poorly soluble drug molecules. Additionally, drugs with an amino 
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acid residue may be substrates for peptide transporters, allowing them to be taken up by 
endogenous transporters in the intestinal epithelium [1]. Of a series of amino acid 
prodrugs of CA-4 amino analogue 5 (Figure 2), serine derivative 5a retained potent 
antiproliferative activity (IC50 value of 27.2 nM in colon 26 cells compared to 2.8 nM for 
5) while improving the solubility in human plasma compared to 5 from 1.4 mg/mL to 3.3 
mg/mL [15]. Prodrug 5a is in clinical trials for advanced-stage soft tissue sarcoma, solid 
tumours and advanced solid tumours [16]. Amino acid prodrugs of combretastatin A-2 
amino derivative 6 (Figure 2) have also been reported, with glycine and tyrosine amides 
possessing the most potent antiproliferative effects (mean IC50 value of 20 nM for glycine 
derivative 6a and 17 nM for tyrosine derivative, compared to 13 nM for 6, across a panel 
of six human cell lines). The amide prodrugs of 6 displayed little inhibition of tubulin 
polymerisation in vitro, indicating a requirement for bioactivation [17]. 
 
β-Lactams for further development were selected from our previous studies on the basis 
of their potency in antiproliferative assays and the presence of suitable functional groups 
(phenolic and amino) for modification (7-11, Figure 3) [4, 5, 18]. The aim of this work 
was to synthesise water-soluble β-lactams with potent antiproliferative effects for 
pharmaceutical use and to characterise their biochemical effects. 
 
2. Chemistry 
Phosphate esters of three potent phenolic β-lactams (7, 8 and 9) [4, 5] were prepared in 
two steps (Scheme 1). Benzyl-protected compound 9c was used to achieve selective 
esterification of the phenol at the C-4 position of 9. Reaction with dibenzylphosphite was 
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achieved using diisopropylethylamine (DIPEA) and dimethylaminopyridine (DMAP) to 
give 7b, 8b and 9b in yields up to 74% (Scheme 1, step a). Introduction of the 
dibenzylphosphite group to the phenol of the β-lactam was confirmed by the appearance 
of signals integrating for 4 protons at approximately δ 5.15 ppm in the 1H NMR spectra 
of 7b, 8b and 9b, attributable to the benzylic CH2 protons. The final step was 
hydrogenolysis of the benzyl protecting groups to prepare 7a, 8a and 9a in high yields 
(Scheme 1, step b). The deprotection of 7b was initially achieved in 72% yield by 
treatment with bromotrimethylsilane. Debenzylation (H2/PdC) of the β-lactam 
intermediates in high yield was successful without decomposition of the β-lactam ring.  
 
Initial investigation into potential amino acid prodrugs of 7 were directed at preparation 
of amino acid esters. The Cbz-protected alanine ester 7e and phenylalanine ester 7f along 
with N-acetyl glycine ester 7g, were obtained by DCC/DMAP coupling of the phenolic 
moiety of 7 with the appropriate amino acids (Scheme 2). Removal of the Cbz protecting 
group from 7e afforded the alanine ester 7h. However, isolation of the corresponding 
phenylalanine and glycine esters proved difficult due to very rapid hydrolysis to the 
phenol 7. The preparation of a number of additional Cbz protected amino acid esters of 7 
was investigated, but in each case the deprotected ester was rapidly hydrolysed. These 
esters are not suitable for further prodrug development. The acetate and benzoate esters 7i 
and 7j were prepared by Staudinger reaction of corresponding imines 12a and 12b with 
phenylacetyl chloride. A basic ether derivative 7l was also synthesised (Scheme 2). The 
ether linkage would not be susceptible to hydrolysis in vivo while the basic side chain 
may improve the water solubility of the derivative. Reaction of the imine 12c with 1,2-
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dibromoethane afforded the bromide 12d, which was then treated with phenylacetyl 
chloride to produce the β-lactam product 7k. Reaction of the bromide 7k with 
methylamine afforded the required product 7l in low yield (30%) as the basic reaction 
conditions resulted in extensive cleavage of the β-lactam ring. 
 
In order to prepare further amino acid β-lactams amides, amino-containing azetidinones 
10 and 11 [4] were coupled to a series of protected L-amino-amino acids. DCC, with 
DMAP and HOBt.H2O, was used to couple either 10 or 11 to the carboxylate moiety of 
amino acids to afford the products 10a-10f and 11a-11h (Schemes 3 and 4). Use of 
polymer-supported DCC gave higher yields and led to more facile isolation of the 
product. This resin contains 1% cross-linked poly(styrene-co-divinylbenzene) with a 
typical loading of 1.3 mmol/g of carbodiimide. The amino group of the amino acid was 
protected during the coupling reaction with either Fmoc or Cbz. Selected amino acid 
precursors (serine and tyrosine) also required benzyl protection of their phenolic groups 
(compounds 10d, 11f and 11g). The required lysine precursor was available with both 
amino groups protected with the Fmoc group. Products were obtained in yields of over 
44% with the exception of lysine-analogue 10c (6%).  
 
Initially the Fmoc-group was cleaved using the base piperidine [19, 20]. When 5% 
piperidine in dichloromethane [21] was used to remove the Fmoc-group from amino acid-
β-lactam conjugates, difficulties in purification of the product arose. A second method 
using tetrabutylammonium fluoride (TBAF, 2 equivalents) and a thiol (1-octanethiol, 10 
equivalents) to scavenge the liberated dibenzofulvene was investigated. This method 
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removes the Fmoc group from a variety of amino acid conjugates in up to 100% yield 
within 1 minute [22]. It was successfully applied to remove the Fmoc group from the β-
lactam derivatives 10a-10d and 11a - 11g (Scheme 3), giving easily isolated products 10g 
- 10j and 11i - 11o in high yield, in less than 10 minutes as monitored by TLC. Cbz- and 
Bn-groups were removed by hydrogenolysis (H2/PdC) from intermediates 10e, 10f, 10j, 
11h, 11n and 11o to afford compounds 10k, 10l, 10m, 11p, 11q and 11r respectively 
(Scheme 4). 
 
3. Solubility 
Selected compounds 9, 9a, 10, 10g, 11 and 11l were shown to be stable in stable in the 
pH range 4-9 and in human plasma, with half-lives greater than 24 h (data not shown). 
The solubility of the novel β-lactam derivatives was measured and compared to that of 
the parent compounds. The phosphate derivatives showed increased aqueous solubility 
compared to the insoluble parent compounds (Table 1). The phenolic β-lactams 7, 8 and 9 
did not display any detectable aqueous solubility, while phosphate derivatives 7a, 8a and 
9a were soluble at 0.3 mg/mL, 0.14 mg/mL and 0.45 mg/mL respectively in water, 
greater than the recommended minimum solubility of 0.05 mg/mL which is desirable for 
potential drug candidates [23]. The increase in solubility is reflective of the increase in 
hydrophilicity of the molecules, as indicated by their lower cLogP values (Table 1). All 
amino acid β-lactam amides assessed showed increased aqueous solubility compared to 
parent β-lactams 10 and 11 (Tables 2 and 3). The highest solubility was obtained with the 
alanine derivative 11j (0.37 mg/mL), which again is favourable compared to the 
minimum desired value of 0.05 mg/mL. The observed increase in solubility due to the 
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phosphate or amino acid group improves the pharmacokinetic profile of the parent 
compound. Amide 7g and amine 7l were not useful as water soluble compounds. 
 
4. Biochemical Results and Discussion 
4.1. Antiproliferative Effects of Phosphate Ester and Amino Acid Amide β-Lactams 
Stilbene 2 was insoluble in water and the development of 2a represented the most 
successful prodrug of 2; it retained the activity of the parent compound, had improved 
solubility and good stability [8]. Phosphate esters of three phenolic β-lactam compounds 
with potent IC50 values in antiproliferative assays (7, 8 and 9) were prepared to 
investigate if improvements in aqueous solubility could be obtained without 
compromising antiproliferative activity. The antiproliferative activities of parent 
compounds were also previously demonstrated in a variety of cell types in the NCI cell 
line screen [4, 5]. The antiproliferative activity of all compounds was assessed using 
human breast carcinoma MCF-7 cells.  
 
The β-lactam phosphate esters 7a, 8a and 9a had IC50 values of 71 nM, 20 nM and 22 nM 
respectively and had slightly decreased potency compared to the corresponding parent 
compounds (Table 1). The IC50 values for the phosphate esters follow approximately the 
same trend as their parent compounds, as 8 and 9 are more potent than 7, with 8a and 9a 
are more potent than 7a.  
 
The antiproliferative activity of β-lactam amino acid conjugates 10g-10i, 10k-10m, 11i-
11m and 11p-11r was assessed (Tables 2 and 3). Derivatives of compound 10 were 
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extremely potent (Table 2), with alanine derivative 10h, phenylalanine derivative 10k 
and valine derivative 10l showing activity greater than or equal to that of the parent 
amino compound 10 (IC50 values of 27 nM, 35 nM and 51 nM respectively compared to 
51 nM for 10). Valine derivative 11l (IC50 value of 460 nM) was the most potent 
derivative of 11. Alanine (11j), serine (11q) and tyrosine (11r) derivatives also had IC50 
values in the nanomolar range comparable to that of the parent compound 11 (760 nM, 
780 nM and 740 nM respectively, 650 nM for 11). 
 
4.2. Effects on Tubulin Polymerisation 
Inhibition of tubulin polymerisation for existing phosphate prodrugs 1a, 2a and 4a differ, 
with intact 1a [6] and 2a [24] displaying no intrinsic tubulin binding affinity while 4a 
displays 40% of the activity of the parent compound 4 [14]. The effects of 5a on in vitro 
tubulin polymerisation have not been reported, but it is known that amino acid amide 
derivatives of 6, including 6a, do not inhibit the polymerisation of tubulin at 
concentrations up to 40 μM [17]. It has previously been demonstrated that compounds 7, 
8 and 9 inhibit the polymerisation of tubulin [4, 5]. Representative β-lactams 7a and 9a 
(phosphate esters) and 10k and 11l (amino acid amides) were selected for in vitro tubulin 
polymerisation studies. 
 
Phosphate β-lactam esters 7a and 9a did not inhibit the in vitro polymerisation of tubulin 
at a concentration of 10 μM (Figure 4). Given their potent antiproliferative effects in 
MCF-7 cells, this result indicates that bioconversion is necessary for the biochemical 
effects of the phosphate compounds. In contrast, the amino acid β-lactam conjugates 10k 
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and 11l inhibited in vitro polymerisation of tubulin in a concentration dependent manner 
(shown for 11l in Figure 5), with IC50 values of 2.4 µM and 5.2 µM respectively. This 
indicates that bioconversion is not necessary for these compounds, although in vivo 
cleavage of the amide linkage is extremely likely to occur. For example, it has been 
reported that aminopeptidases on the surface of erythrocytes catalyse the cleavage of 5a 
to 5 [21].  
 
4.3. Immunofluorescence Studies 
In addition to in vitro tubulin polymerisation studies, we investigated alterations in the 
microtubule network induced by β-lactams 8a, 9a, 10k and 11l in MCF-7 cell culture by 
confocal microscopy. Confocal analysis of MCF-7 cells stained with α-tubulin mAb 
demonstrated a well organised microtubular network in control cells (Figure 6, A+E and 
Figure 7, A+D). Exposure to any of the four β-lactam conjugates 8a, 9a, 10k and 11l for 
16 h led to a complete loss of microtubule formation consistent with depolymerised 
microtubules (Figures 6 and 7). Additionally, cells treated with β-lactams 8a, 9a, 10k and 
11l contained multiple micronuclei - a phenomenon described as mitotic catastrophe. 
Mitotic catastrophe is a type of programmed cell death in response to DNA damage, 
characterised by multinucleated cells [25]. We have previously noted mitotic catastrophe 
for related β-lactam derivatives [26]. The findings are in agreement with previously 
published studies, where 2 induced mitotic catastrophe in non-small cell lung cancer cells 
[27, 28] and 2a in chronic lymphocytic leukaemia cells [29]. Mitotic catastrophe has also 
been demonstrated for 2 and related derivatives in both human endothelial cells 
(HUVEC), human lung carcinoma cells (H460) [30] and human breast cancer cells 
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(MCF-7) [26]. The confocal imaging results confirm that both the phosphate and amino 
acid β-lactam conjugates are targeting tubulin. 
 
4.4. Analysis of DNA Content by Flow Cytometry 
We next examined the effects of 2, parent β-lactams 7, 8 and 9 and β-lactam derivatives 
7a, 8a, 9a, 10k and 11l on the cell cycle of MCF-7 cells by flow cytometric analysis of 
propidium iodide stained cells (Figure 8). In this whole-cell assay, both phosphate and 
amino acid β-lactam prodrugs caused increases in the percentage of cells in the sub-G1 
and G2/M phases, indicative of apoptosis and G2/M arrest respectively. There were no 
significant differences in the percentage of cells in sub-G1 and G2/M phases between the 
parent β-lactams and the derivatives. 
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5. Molecular Modelling Studies  
The tubulin binding and immunofluorescence studies clearly demonstrate that tubulin is 
the target of the new β-lactam derivatives. Based on structural similarities between 2 and 
the β-lactams reported in this study, we propose that they interact with the colchicine 
binding site of tubulin as demonstrated for 2 and structurally related, conformationally 
constrained analogues of 2 [30-32]. Molecular modelling studies were performed to 
investigate potential interactions for the intact β-lactam amino acid amides 10k and 11l, 
considering that they inhibited tubulin polymerisation without chemical or enzymatic 
modification. The reported X-ray structure of tubulin cocrystallized with a colchicine 
derivative, N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine, PDB entry 
1SA0) was used for the docking study [33]. β-Lactams were isolated as racemic mixtures 
and the presence of two enantiomers has been demonstrated [4]. Molecular modelling 
studies were carried out with both enantiomers and results of the best fitting 3S*,4R* 
enantiomer are illustrated. The β-lactam phosphate esters 7a, 8a and 9a had no effect in 
the in vitro tubulin polymerisation assay, indicating that hydrolysis is required for their 
effects, and therefore no molecular modelling was investigated for those compounds. 
 
Molecular docking studies of parent compounds 10 and 11 (Figures 9A and 10A) 
predicted similar interactions to those previously reported to be of importance for binding 
at the colchicine site, including important interactions with Cys241 and Val318 [33, 34]. 
Additionally, there is direct bond between compound 11 and the Met259 residue. Both 
compounds are orientated in a similar manner to DAMA-colchicine, with the 3,4,5-
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trimethoxyaryl A ring and 4-methoxyaryl B ring occupying the same position in the 
binding pocket (Figures S1 and S3, Supplementary Information). 
 
Comparison of the docked structures of 10 and 10k indicated that the core β-lactam, A 
and B rings are orientated in the same way in the binding pocket (Figure 9A and B, and 
Figures S1 and S2, Supplementary Information). All but one of the 24 binding contacts 
for 10 are also predicted for 10k, the exception being an interaction with Asn249. The 
phenylalanine substituent on ring C extends further and makes numerous additional 
contacts, for example with Lys254 and Lys352 (Figure 9B). We have previously shown 
that bulky substituents directly attached to ring C are detrimental to activity [4]. In this 
series of β-lactams the potency of 10k in MCF-7 cells indicates that the linear chain 
linking the two aromatic rings (ring C to the aromatic ring of phenylalanine) is essential 
to maintain potent in vitro activity. 
 
The docked structures of 11 and 11l are illustrated in Figure 10. Additional binding 
interactions associated with the valine moiety are predicted for 11l, namely with Gln11, 
Gly143, Ser178, Glu183, Tyr224 and Gln247. The predicted docking position for both 
the core β-lactam and A rings is similar for these two structures. However, the 
positioning of the B and C rings of both compounds is different (Figures S3 and S4, 
Supplementary Information). We have previously noted this ‘flip’ in relative orientation 
of the B and C rings for β-lactams when larger substitutents are present on ring B [26]. 
The orientation predicted for 11l is consistent with our previous experience that bulky 
substitution to the B ring forces a change in molecular orientation within the colchicine 
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binding site. This is not necessarily associated with a decrease in antiproliferative 
activity, as 11l is more potent in MCF-7 cells than 11. However, we must once again 
emphasize that hydrolysis to yield the parent amine compounds 10 and 11 is predicted to 
occur in vivo prior to interaction with tubulin. These in silico studies provide useful 
information for the development of future antiproliferative agents that interact with the 
colchicine binding site of tubulin, possibly exploiting the additional binding interactions 
predicted for 10k and 11l. 
 
6. Discussion 
Our previously reported β-lactams are amongst the most potent analogues of 2 known, 
with selected compounds showing sub-nanomolar antiproliferative activity (e.g. IC50 for 
9 in MCF-7 cells is 0.8 nM). However, these compounds are not sufficiently water 
soluble for further development and a prodrug strategy was devised to improve this 
physiochemical characteristic. Potentially useful prodrugs were synthesised including 
three β-lactam phosphate esters, two β-lactam esters and eighteen amino acid amides. A 
number of novel compounds exhibited greatly improved aqueous solubility compared to 
the parent compounds.  
 
The primary in vitro degradation pathway of concern for phosphates is hydrolysis, and 
the electronic environment and substitution on the prodrug moiety may have profound 
effects on stability [35]. Two previously reported prodrugs of 2 were found to be stable in 
aqueous solution [36]. When the stability of phosphate ester prodrugs 2a and 3a was 
evaluated in murine plasma, there was little evidence of dephosphorylation even after 3 
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hours. In contrast, 2a and 3a were rapidly dephosphorylated in tumor (MAC29) and liver 
preparations [37]. It is expected that rapid in vivo dephosphorylation would occur for the 
β-lactam phosphates 7a, 8a and 9a in a manner similar to that documented for 2a [12]. In 
vitro, a selection of representative β-lactam phosphate esters were demonstrated to be 
stable in the pH range 4-9 and in plasma, with half-lives greater than 24 hours. The β-
lactam amino acid amides are also stable at three pH values (Table 4). These amides are 
expected to be hydrolysed by peptidases in vivo in a similar fashion to 5a [21]. Further 
detailed stability studies on the β-lactam phosphate esters and amino acid amides are 
ongoing. 
 
Biochemical profiling of the β-lactam derivatives confirmed their antiproliferative and 
tubulin-targeting effects. For both series of compounds, antiproliferative activity was 
noted in the nanomolar concentration range, with 8a, 9a, 7a and 10k having the lowest 
IC50 values (20, 22, 71 and 27 nM respectively). Immunofluorescence microscopy studies 
showed disruption of the microtubule network and mitotic catastrophe for both the 
phosphate and amino acid series of analogues. In cell-cycle analysis the percentage of 
cells in sub-G1 (indicative of cell death) was significantly increased compared to the 
control. 
 
In the antiproliferative, immunofluorescence and cell cycle analysis assays, whole cells 
are used and it is expected that bioconversion of the β-lactam derivatives to the parent 
compounds is possible. Both series of compounds had the same potent biochemical 
effects in these assays. However, we noted a significant difference between the phosphate 
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and amino acid analogues in the tubulin polymerisation assay, which uses isolated, 
purified tubulin and in which metabolic enzymes are not present. In this assay, the 
phosphate prodrugs did not inhibit tubulin polymerisation. The amino acid β-lactam 
conjugates, taking 10k and 11l as representative examples, inhibited tubulin 
polymerisation in vitro in the absence of enzymatic action. These results indicate that the 
phosphate derivatives are true prodrugs requiring enzymatic activation, while the intact 
amino acid derivatives are microtubule poisons in their own right. However, due to the 
widespread presence of aminopeptidases in the blood, it is likely that they may be 
hydrolysed in vivo before reaching their target site of action. Regardless of this, we have 
demonstrated they can act as microtubule depolymerisers in either form.  
 
7. Conclusion 
We describe the synthesis and biochemical effects of novel series of antiproliferative 
phosphate ester and amino acid amide β-lactam derivatives, designed to overcome the 
pharmacokinetic hurdle of poor aqueous solubility observed for previously reported 
compounds [4]. The novel compounds displayed increased aqueous solubility, which is 
an advantage for drug delivery. The strategic modification of previously described β-
lactam CA-4 derivatives by inclusion of phosphate or amino acid moieties did not 
adversely influence their antiproliferative and tubulin targeting properties, as determined 
by antiproliferative assays, cell cycle assays and analysis of the microtubular network by 
confocal microscopy. Novel derivatives had nanomolar antiproliferative IC50 values in 
MCF-7 cells and disrupted the microtubule network. The potent activity and microtubule 
disrupting effects of the β-lactam derivatives warrants further investigations. 
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8. Experimental Methods 
All reagents were commercially available and were used without further purification 
unless otherwise indicated. IR spectra were recorded as thin films on NaCl plates or as 
KBr discs on a Perkin-Elmer Paragon 100 FT-IR spectrometer. 1H and 13C NMR spectra 
were obtained on a Bruker Avance DPX 400 instrument at 20oC, 400.13MHz for 1H 
spectra, 100.61MHz for 13C spectra, in CDCl3, CD3OD or DMSO-d6 (internal standard 
tetramethylsilane) by Dr. John O’Brien and Dr. Manuel Ruether in the School of 
Chemistry, Trinity College Dublin. High resolution accurate mass determinations 
(HRMS) for all final target compounds were obtained on a Micromass Time of Flight 
mass spectrometer equipped with electrospray ionisation (ES) interface operated in the 
positive ion mode at the High Resolution Mass Spectrometry Laboratory by Dr. Martin 
Feeney in the School of Chemistry, Trinity College Dublin. Thin layer chromatography 
was performed using Merck Silica gel 60 TLC aluminium sheets with fluorescent 
indicator visualizing with UV light at 254 nm. Flash chromatography was carried out 
using standard silica gel 60 (230-400 mesh) obtained from Merck. Analytical high-
performance liquid chromatography (HPLC) to determine the purity of the final 
compounds was performed using a Waters 2487 Dual Wavelength Absorbance detector, a 
Waters 1525 binary HPLC pump, a Waters In-Line Degasser AF and a Waters 717plus 
Autosampler. The column used was a Varian Pursuit XRs C18 reverse phase 150 x 4.6 
mm chromatography column. Samples were detected using a wavelength of 254 nm. All 
samples were analysed using acetonitrile (70%): water (30%) over 10 min and a flow rate 
of 1 mL/min. The purity of the tested compounds was >95%. Polymer-supported DCC 
was obtained from (Biotage®). Syntheses of imine 12c [18] and β-lactams 7, 8, 9, 10 and 
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11 [4, 5] were achieved as previously reported. Experimental characterisation of 
compounds 8a, 8b, 9a, 9b, 10a-10d, 10f-10j, 10l, 10m, 11a-11c, 11e-11k, 11m-11r is 
contained in the supplementary information. 
 
8.1 Chemical Synthesis 
8.1.1. General procedure for synthesis of imines  
The appropriate amine (10 mmol) was refluxed with the appropriate aldehyde (10 mmol) 
in ethanol (50 mL) for 3 h. The reaction mixture was reduced in vacuo, and the resulting 
solution was allowed to stand until solid product crystallized from solution. The resulting 
imine was recrystallized from ethanol. 
8.1.1.1. 2-Methoxy-5-(((3,4,5-trimethoxyphenyl)imino)methyl)phenyl acetate (12a) 
was obtained from 3,4,5-trimethoxyaniline and 5-formyl-2-methoxyphenyl acetate as a 
white powder (64% yield); mp 120 °C; IR (KBr disk) υmax: 1608 cm-1 (C=N); 1H NMR 
(400 MHz, CDCl3) δ 2.22 (s, 3H, CH3), 3.85 (m, 12H, OCH3), 6.51 (s, 2H, ArH), 7.08 (d, 
1H, J=4.5 Hz, ArH), 7.28 (s, 1H, ArH), 7.79 ( m, 1H, ArH), 8.39 (s, 1H, C=N); HRMS: 
calculated for C19H22NO6: 360.1449; found 360.1430 [M+H]
+. 
8.1.1.2. 2-Methoxy-5-(((3,4,5-trimethoxyphenyl)imino)methyl)phenyl benzoate (12b) 
was obtained from 3,4,5-trimethoxyaniline and 5-formyl-2-methoxyphenyl benzoate as 
peach coloured crystals (75% yield); mp 120 °C; IR (KBr disk) υmax: 1611 cm-1 (C=N); 
1H NMR (400 MHz, CDCl3) δ 3.90 (m, 12H, OCH3), 7.11 (s, 1H, ArH), 7.28 (s, 2H, 
ArH), 7.55 (m, 2H, ArH), 7.67 (m,1H, ArH), 7.83 (m, 2H, ArH), 8.24 (d, 2H, J=1 Hz, 
ArH), 8.43 (s, 1H, C=N); HRMS: calculated for C24H24NO6: 422.1604; found  
422.1582[M+H]+. 
 20 
 
8.1.2. General procedure for synthesis of 7b, 8b and 9b 
Carbon tetrachloride (85 mmol) was added to a solution of appropriate phenol (17 mmol) 
in acetonitrile (100 mL) at 0 °C. The resulting solution was stirred for 10 minutes prior to 
addition of diisopropylethylamine (35 mmol) and DMAP (1.7 mmol). Then, dibenzyl 
phosphite (24.5 mmol) was added dropwise. When the reaction was complete as 
indicated by TLC, KH2PO4 (aq., 0.5 M) was added and the mixture was allowed to warm 
to room temperature. An ethyl acetate extract (3 × 50 mL) was washed with saturated 
NaCl (100 mL) followed by water (100 mL) and dried over anhydrous Na2SO4. The 
solvent was evaporated under reduced pressure and the product isolated by flash column 
chromatography (hexane: ethyl acetate gradient, 88:12 to 50:50). 
 
8.1.2.1. Dibenzyl (2-methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-
2-yl)phenyl) phosphate (7b) was prepared according to the general procedure above 
from 4-(3-hydroxy-4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (7) in 74.3% yield as a yellow oil; IR (NaCl film) νmax: 1750 cm-1 (β-lactam -C=O); 
1H NMR (400 MHz, CDCl3) δ 3.73 (s, 6H, 2 × OCH3), 3.78 (s, 3H, OCH3), 3.84 (s, 3H, 
OCH3), 4.25 (d, 1H, J=2 Hz, H3), 4.78 (d, 1H, J=2 Hz, H4), 5.15-5.18 (m, 4H, CH2), 6.60 
(s, 2H, ArH), 6.98 (d, 1H, J=8 Hz, ArH), 7.20 (m, 2H, ArH), 7.33-7.41 (m, 15H, ArH); 
13C NMR (100 MHz, CDCl3) δ 55.6 (OCH3), 55.6 (OCH3), 60.5 (OCH3), 62.9 (C3), 64.5 
(C4), 69.5 (OCH2), 69.6 (OCH2), 94.3 (CH, Ar), 112.9 (CH, Ar), 119.3 (CH, Ar), 122.8 
(CH, Ar), 127.0 (CH, Ar), 127.4 (CH, Ar), 127.5 (CH, Ar), 127.6 (CH, Ar), 128.2 (CH, 
Ar), 128.2 (CH, Ar), 128.6 (CH, Ar), 133.1 (C, Ar), 134.0 (C, Ar), 153.1 (C, Ar), 165.0 
(C=O); HRMS: calculated for C39H38NO9PNa: 718.2182; found 718.2172 [M+Na]
+. 
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8.1.3. General method for synthesis of phosphates 7a, 8a and 9a  
β-Lactams 7b, 8b or 9b (2 mmol) were dissolved in ethanol: ethyl acetate (50 mL; 1:1 
mixture) and hydrogenated over 10% Pd/C (1.2 g) until complete on TLC; typically less 
than 3 hours. The catalyst was removed by filtration through Celite, the solvent was 
evaporated under reduced pressure and the product was isolated by flash column 
chromatography (hexane: ethyl acetate gradient, 88:12 to 50:50). 
 
8.1.3.1. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-
yl)phenyl dihydrogen phosphate (7a) was prepared from 7b as described in the general 
method above. The product was obtained as a brown oil in 93% yield; IR (KBr disk) νmax: 
1747 cm-1 (β-lactam -C=O); 1H NMR (400 MHz, DMSO-d6) δ 3.59 (s, 3H, OCH3), 3.67 
(s, 6H, 2 × OCH3), 3.77 (s, 3H, OCH3), 4.43 (d, 1H, J=2.5 Hz, H3), 5.24 (d, 1H, J=2.5 Hz, 
H4), 6.63 (s, 2H, ArH), 7.09 (d, 1H, ArH, J=8.5 Hz), 7.35 (m, 1H, ArH), 7.36-7.42 (m, 
5H, ArH), 7.51 (s, 1H, ArH); 13C NMR (100 MHz, DMSO-d6) δ 56.1 (OCH3), 56.2 
(OCH3), 60.5 (OCH3), 62.2 (C3), 64.0 (C4), 95.5 (CH, Ar), 113.7 (CH, Ar), 119.6 (CH, 
Ar), 122.9 (CH, Ar), 127.9 (CH, Ar), 128.0 (CH, Ar), 128.2 (CH, Ar), 128.7 (CH, Ar), 
129.4 (CH, Ar), 129.7 (CH, Ar), 133.5 (C, Ar), 134.3 (C, Ar), 135.2 (C, Ar), 150.9 (C, 
Ar), 151.0 (C, Ar), 153.6 (C, Ar), 165.8 (C=O); HRMS: Calculated for C25H26NNaO9PS: 
538.1243; found 538.1252 [M+Na]+. 
 
8.1.4. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl 
2-(((benzyloxy)carbonyl)amino)propanoate (7e). N-Benzyloxycarbonyl-L-alanine 
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(0.23 mmol), DCC (0.23 mmol) and DMAP (0.23 mmol) were stirred in anhydrous DCM 
(5 mL) at 0 ºC. A solution of the β-lactam 7 (0.23 mmol) in anhydrous DCM (5 mL) was 
added dropwise over five min. The reaction was stirred for 16 h under a nitrogen 
atmosphere at ambient temperature. Reaction was monitored via TLC. After 24 hours, 
dichloromethane (50 mL) was added and the mixture was filtered. The solvent was 
removed by washing with water (5 × 50 mL). The organic solvent containing the product 
was evaporated under reduced pressure. The product was isolated by flash column 
chromatography (dichloromethane: methanol gradient), to afford the product 7e (88%). 
IR (NaCl film) νmax: 1752.9 (β-lactam -C=O); 1H NMR (400 MHz, CDCl3) δ 1.62 (3H, d, 
J=7 Hz, CH3), 3.75-3.92 (m, 12H, 4 × OCH3), 4.30-4.32 (m, 1H, H3), 4.69 (1H, q, J=7 
Hz, CH), 4.83-4.87 (m, 0.5H, CH, H4), 5.15-5.44 (m, 0.5H, CH, H4), 5.39-5.44 (2H, m, 
OCH2), 6.61-6.64 (2H, m, ArH), 6.88-6.95 (m, 1H, ArH), 7.01-7.03 (m, 1H, ArH), 7.16-
7.17 (m, 1H, ArH), 7.29-7.41 (m, 10H, ArH).13C NMR (100 MHz, CDCl3) δ 18.7 (CH3), 
18.8 (CH3), 49.7 (C), 56.1 (OCH3), 60.9 (OCH3), 63.4 (C3), 63.8 (C3), 64.9 (C4), 65.0 
(CH2), 67.1 (CH2), 94.8 (CH, Ar), 94.9 (CH, Ar), 111.1 (CH, Ar), 112.0 (CH, Ar), 113.1 
(CH, Ar), 113.1 (CH, Ar), 117.8 (CH, Ar), 120.8 (CH, Ar), 124.6 (CH, Ar), 124.6 (CH, 
Ar), 127.5 (CH, Ar), 127.9 (CH, Ar), 128.0 (CH, Ar), 128.1 (CH, Ar), 128.2 (CH, Ar), 
128.6 (CH, Ar), 129.0 (CH, Ar), 129.1 (CH, Ar), 129.9 (CH, Ar), 130.5 (CH, Ar), 133.6 
(C, Ar), 133.7 (C, Ar), 134.5 (C, Ar), 134.5 (C, Ar), 134.8 (C, Ar), 136.2 (C, Ar), 139.9 
(C, Ar), 146.4 (C, Ar), 146.9 (C, Ar), 151.2 (C, Ar), 153.5 (C, Ar), 153.6 (C, Ar), 155.6 
(C, Ar), 165.5 (C=O), 165.6 (C=O), 171.0 (C=O), 171.1 (C=O); HRMS: Calculated for 
C36H36N2O9Na: 663.2319; Found 663.2332 [M+Na]
+. 
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8.1.5. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl 
2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoate (7f). N-Benzyloxycarbonyl-L-
phenylalanine (0.23 mmol), DCC (0.23 mmol) and DMAP (0.23 mmol) were stirred in 
anhydrous DCM (5 mL) at 0 ºC. A solution of 7 (0.23 mmol) in anhydrous DCM (5 mL) 
was added dropwise over five min. Following the method described above for the 
preparation of 7e, the product 7f was isolated (79%). IR (NaCl film) νmax: 1754.7 (β-
lactam -C=O); 1H NMR (400 MHz, CDCl3) δ 3.24-3.38 (m, 2H, CH2), 3.75-3.86 (m, 
12H, 4 × OCH3), 4.32 (m, 1H, H3), 4.87 (m, 1H, H4), 4.95-4.99 (m, 1H, CH), 5.13 (s, 2H, 
CH2 ), 6.63 (s, 2H, ArH), 7.00-7.04 (m, 2H, ArH), 7.29-7.42 (m, 16H, ArH). 
13C NMR 
(100 MHz, CDCl3) δ 37.6 (CH2), 37.7 (CH2), 54.3 (C), 55.5 (OCH3), 55.6 (OCH3), 60.5 
(OCH3), 62.9 (C3), 64.5 (C4), 66.6 (OCH2), 94.3 (CH, Ar), 112.6 (CH, Ar), 112.7 (CH, 
Ar), 120.4 (CH, Ar), 124.2 (CH, Ar), 126.8 (CH, Ar), 127.0 (CH, Ar), 127.6 (CH, Ar), 
127.8 (CH, Ar), 128.1 (CH, Ar), 128.2 (CH, Ar), 128.3 (CH, Ar), 128.7 (CH, Ar), 128.8 
(CH, Ar), 129.0 (CH, Ar), 129.1 (CH, Ar), 129.4 (CH, Ar), 129.5 (CH, Ar), 133.1 (C, 
Ar), 134.0 (C, Ar), 134.1 (C, Ar), 135.0 (C, Ar), 135.1 (C, Ar), 139.3 (C, Ar), 150.9 (C, 
Ar), 153.1 (C, Ar), 155.2 (C, Ar), 164.9 (C=O), 165.0 (C=O), 169.1 (C=O), 169.2 (C=O); 
HRMS: Calculated for C42H41N2O9: 717.2812; found 717.2813 [M+H]
+. 
 
8.1.6. Acetylamino-acetic acid 2-methoxy-5-[4-oxo-3-phenyl-1-(3,4,5-trimethoxy-
phenyl)azetidin-2-yl]phenyl ester (7g). N-Acetylglycine (0.23 mmol), DCC (0.23 
mmol) and DMAP (0.23 mmol) were stirred in anhydrous DCM (5 mL) at 0 ºC. A 
solution of 7 (0.23 mmol) in anhydrous DCM (5 mL) was added dropwise over five min. 
The reaction was stirred for 16 h under a nitrogen atmosphere at ambient temperature. 
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Reaction was monitored via TLC. After 24 hours, dichloromethane (50 mL) was added 
and the mixture was filtered. The solvent was removed by washing with water (5 × 50 
mL). The organic solvent containing the product was evaporated under reduced pressure. 
The product was isolated by flash column chromatography (dichloromethane: methanol 
gradient), to afford the product (72%). IR (NaCl film) νmax: 1753.3 (β-lactam -C=O); 1H 
NMR (400 MHz, CDCl3) δ 2.07 (s, 3H, CH3), 3.73 (s, 6H, 2 × OCH3), 3.79 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3), 4.29 (d, 1H, J=2.5 Hz, H3), 4.32-4.33 (m, 2H, CH2), 4.86 (d, 
1H, J=2 Hz, H4), 6.60 (s, 2H, ArH), 7.02 (d, 1H, J=8.5 Hz, ArH), 7.15 (m, 1H, ArH), 
7.31-7.41 (m, 6H, ArH). 13C NMR (100 MHz, CDCl3) δ 22.5 (CH3), 40.7 (CH2), 55.6 
(OCH3), 60.5 (OCH3), 62.9 (C3), 64.5 (C4), 94.3 (CH, Ar), 112.7 (CH, Ar), 120.2 (CH, 
Ar), 124.3 (CH, Ar), 126.9 (CH, Ar), 127.6 (CH, Ar), 128.6 (CH, Ar), 129.5 (CH, Ar), 
133.1 (C, Ar), 133.9 (C, Ar), 134.0 (C, Ar), 139.3 (C, Ar), 150.8 (C, Ar), 153.1 (C, Ar), 
165.0 (C=O), 167.7 (C=O), 169.9 (C=O); HRMS: Calculated for C29H30NO8Na: 
557.1900; found 557.1917 [M+Na]+. 
 
8.1.7. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl 
acetate (7i). The imine 12a (5mmol) and triethyl amine (15 mmol) were added to 
anhydrous dichloromethane (50 mL) and the mixture heated to reflux under nitrogen 
atmosphere. Acetyl chloride (7.5 mmol) was injected dropwise through a septum, and the 
mixture was allowed to reflux for 3 h. The reaction mixture was then cooled, washed 
with water, (2 × 50 mL) and sodium bicarbonate solution (aq., 50 mL). The organic layer 
was dried with anhydrous Na2SO4, and the solvent evaporated to dryness in vacuo. The 
residue was purified by flash chromatography (hexane ethyl acetate, 50:50) to afford the 
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β-lactam product as colourless crystals from methanol (7%), Mp 70 oC. IR (KBr disk) 
νmax: 1725.1 (β-lactam -C=O); 1H NMR (400 MHz, CDCl3) δ 2.12 (3H, s, CH3), 3.75 
(6H, s, 2 × OCH3), 3.80 (3H, s, OCH3), 3.87 (3H, s, 2 × OCH3), 4.32 (1H, d, J=2.5 Hz, 
H3), 4.86 (1H, d, J=2.5 Hz, H4), 6.64 (2H, s, ArH), 7.02 (1H, m, ArH), 7.13(1H, d, J=2 
Hz, ArH), 7.27-7.40 (6H, m, ArH); HRMS: Calculated for C27H27NO7Na: 500.1685; 
found: 500.1688 [M+Na]+. 
 
8.1.8. 2-Methoxy-5--4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl 
benzoate (7j). The imine 12b (5mmol) and triethyl amine (15 mmol) were added to 
anhydrous dichloromethane (50 mL) and the mixture heated to reflux under nitrogen 
atmosphere. Phenylacetyl chloride (7.5 mmol) was injected dropwise through a septum, 
and the mixture was allowed to reflux for 3 h, following the method described above for 
the preparation of 7i. The β-lactam product 7j was obtained as colourless crystals from 
methanol (8%), Mp 73 oC. IR (NaCl film) νmax: 1752.0 (β-lactam -C=O); 1H NMR (400 
MHz, CDCl3) δ 3.84 (s, 6H, 2 × OCH3), 3.84 (s, 3H, OCH3), (s, 3H, OCH3), 4.36 (d, 1H, 
J=2.9 Hz, H3), 4.90 (d, 1H, J=2.9 Hz, H4), 6.63 (s, 2H, ArH), 7.07-7.31 (m, 2H, ArH), 
7.35-7.39 (m, 4H, ArH), 7.52-7.83 (m, 4H, ArH), 8.20-8.24, (m, 3H, ArH); HRMS: 
Calculated for C32H29NO7Na: 562.1842; found: 562.1841 [M+Na]
+. 
  
8.1.9. [3-(2-Bromoethoxy)-4-methoxybenzylidene]-(3,4,5-trimethoxyphenyl)amine 
(12d). Imine 12c (5 mmol) and tertabutylammonium sulfate (4.5 mmol) were dissolved in 
dibromoethane (50 mmol). Sodium hydroxide solution (1 M, 40 mL) was added to the 
reaction mixture. The reaction was vigorously stirred for 16 h. Upon completion, the 
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reaction mixture was diluted with dichloromethane (100 mL) and saturated sodium 
hydrogen carbonate (100 mL). The organic phase was separated, while the aqueous phase 
was extracted with dichloromethane (2 × 100 mL). The organic phases were combined, 
dried over Mg2SO4 and evaporated to dryness in vacuo. The resulting crystals were 
recrystallised from ethanol to afford the product (83%); IR (KBr disk) νmax: 1622.8 
(C=N); 1H NMR (400 MHz, CDCl3) δ 3.89-3.97 (m, 12H, 3 × OCH3), 3.74 (t, 2H, J=6.5 
Hz, CH2Br), 4.46 (t, 2H, CH2O), 6.51 (s, 2H, ArH), 6.99 (d, 1H, J=8.5 Hz, ArH), 7.39 (d, 
1H, J=8 Hz, ArH), 7.62 (s, 1H, ArH), 8.40 (s, 1H, HC=N); 13C NMR (100 MHz, CDCl3) 
δ 29.1 (CH2Br), 55.6 (OCH3), 60.6 (OCH3), 68.4 (CH2O), 97.6 (CH, Ar), 110.8 (CH, Ar), 
111.2 (CH, Ar), 124.8 (CH, Ar), 128.8 (CH, Ar), 135.7 (C, Ar), 143.0 (C, Ar), 147.5 (C, 
Ar), 153.1 (C, Ar), 158.4 (C=N); HRMS: Calculated for C19H23NO5Br: 424.0760; found 
424.075 [M+H]+. 
 
8.1.10. 4-[3-(2-Bromoethoxy)-4-methoxyphenyl]-3-phenyl-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (7k). Imine 12d (2.0 mmol) and triethylamine (2.6 
mmol) were dissolved in anhydrous dichloromethane (10 mL). A solution of phenylacetyl 
chloride (2.6 mmol) in anhydrous dichloromethane (5 mL) was added slowly via syringe. 
The reaction was refluxed for two hours, then allowed cool and evaporated to dryness. 
The residue was purified by flash chromatography (hexane: ethyl acetate, 1:1) to afford 
7k as a resin (29%); IR (NaCl film) νmax 1749.8 (β-lactam C=O); 1H NMR (400 MHz, 
CDCl3) δ 3.64 (t, 2H, CH2Br, J=6.5 Hz), 3.75 (s, 6H, OCH3), 3.80 (s, 3H, OCH3), 3.91 (s, 
3H, OCH3), 4.29-4.34 (m, 3H, OCH2, H3), 4.86 (d, 1H, J=2.5 Hz), 6.63 (s, 2H), 6.93-6.96 
(m, 2H), 7.05-7.08 (m, 1H), 7.34-7.40 (m, 5H, ArH); 13C NMR (100 MHz, CDCl3) δ 28.4 
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(CH2Br), 55.6 (OCH3), 59.9 (OCH3), 60.5 (OCH3), 63.4 (C3), 64.5 (C4), 68.9 (OCH2), 
94.4 (CH, Ar), 111.7 (CH, Ar), 112.1 (CH, Ar), 119.7 (CH, Ar), 126.9 (CH, Ar), 127.5 
(CH, Ar), 128.6 (CH, Ar), 129.4 (CH, Ar), 130.5 (CH, Ar), 133.2 (C, Ar), 134.2 (C, Ar), 
147.7 (C, Ar), 149.8 (C, Ar), 153.1 (C, Ar), 165.1 (C=O); HRMS: Calculated for 
C27H28NO6NaBr: 564.0998, found 564.1005 [M+Na]
+. 
 
8.1.11. 4-[4-Methoxy-3-(2-methylaminoethoxy)phenyl]-3-phenyl-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (7l). β-Lactam 7k (0.2 mmol) and methylamine 2.0 M 
solution (4.0 mmol) were dissolved in anhydrous tetrahydrofuran (10 mL) in a high 
pressure tube. The sealed tube was heated to 60 ºC for 6 h. The reaction mixture was 
allowed cool and sodium carbonate/sodium hydrogen carbonate pH 10 buffer solution 
was added (25 mL). The reaction mixture was extracted with dichloromethane (3 × 50 
mL). The combined organic phases were dried over Mg2SO4 and evaporated to dryness in 
vacuo. The residue was purified using flash chromatography (hexane: ethyl acetate, 1:1) 
to afford 7l as a resin (30%); IR (NaCl film) νmax 1746.6 (β-lactam C=O); 1H NMR (400 
MHz, CDCl3) δ 2.70 (s, 3H, NCH3), 3.24 (m, 2H, CH2), 3.75 (s, 6H, OCH3), 3.79 (s, 3H, 
OCH3), 3.88 (s, 3H, OCH3), 4.22-4.30 (m, 3H, CH, OCH2), 4,57 (broad s, 1H, NH), 4.86 
(d, 1H, CH, J=2 Hz), 6.62 (s, 2H, ArH), 6.93-6.96 (m, 2H), 7.05-7.08 (m, 1H), 7.33-7.41 
(m, 5H, ArH); 13C NMR (100 MHz, CDCl3) δ 34.0 (NCH3), 48.6 (CH2), 55.6 (OCH3), 
55.9 (OCH3), 60.5 (OCH3), 63.3 (C3), 64.5 (C4), 66.0 (OCH2), 94.4 (CH, Ar), 102.9 (CH, 
Ar), 111.5 (CH, Ar), 111.7 (CH, Ar), 119.7 (CH, Ar), 127.0 (CH, Ar), 127.5 (CH, Ar), 
127.8 (CH, Ar), 127.9 (CH, Ar), 128.5 (CH, Ar), 128.6 (CH, Ar), 129.7 (CH, Ar), 130.5 
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(CH, Ar), 133.2 (C, Ar), 134.1 (C, Ar), 147.7 (C, Ar), 149.5 (C, Ar), 153.1 (C, Ar), 165.2 
(C=O); HRMS: Calculated for C28H33N2O6: 493.2334; found 493.2337 [M+H]
+. 
 
8.1.12. General method for synthesis of amides 10a-10f and 11a-11h 
To a stirred solution of the appropriate amino β-lactam 10 or 11 (4.76 mmol) in 
anhydrous DMF (30 mL) were added DCC (5.7 mmol), Cbz- or Fmoc-protected L-amino 
acid (5.7 mmol) and HOBt.H2O (7.3 mmol) at room temperature. After 24 hours, ethyl 
acetate (50 mL) was added and the mixture was filtered. DMF was removed by washing 
with water (5 by 50 mL). The organic solvent containing the product was evaporated 
under reduced pressure. The product was isolated by flash column chromatography 
(dichlormethane: methanol gradient). 
 
8.1.12.1. Benzyl (1-((4-(2-(4-methoxyphenyl)-4-oxo-1-(3,4,5-
trimethoxyphenyl)azetidin-3-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamate (10e) was prepared from 10 and Cbz-protected phenylalanine following 
the general method above and was isolated as a yellow gel in 28% yield; IR (NaCl film) 
νmax: 1743 cm-1 (β-lactam -C=O), 1689 cm-1 (-C=O); 1H NMR (400 MHz, CDCl3) δ 3.11-
3.25 (m, 2H, CH2), 3.74 (s, 6H, 2 × OCH3), 3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.01 
(m, 2H, CH2), 4.24 (d, 1H, CH), 4.55 (d, 1H, CH), 4.82 (d, 1H, J=2.5 Hz, H4), 5.49 (s, 
1H), 6.61 (s, 2H, ArH), 6.96 (d, 2H, J=9.0 Hz, ArH), 7.25-7.35 (m, 18H, ArH), 7.67 (s, 
1H, ArH); 13C NMR (100 MHz, CDCl3) δ 38.4 (CH2), 53.0 (CH), 54.9 (OCH3), 55.6 
(OCH3), 60.5 (OCH3), 63.5 (C3), 64.1 (C4), 66.6 (OCH2), 66.9 (OCH2), 94.4 (CH, Ar), 
114.2 (CH, Ar), 120.2 (CH, Ar), 125.4 (CH, Ar), 126.8 (CH, Ar), 127.6 (CH, Ar), 127.7 
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(CH, Ar), 127.9 (CH, Ar), 128.1 (CH, Ar), 128.5 (CH, Ar), 128.7 (CH, Ar), 128.8 (CH, 
Ar), 133.2 (C, Ar), 134.0 (C, Ar), 135.4 (C, Ar), 135.7 (C, Ar), 153.0 (C, Ar), 159.5 (C, 
Ar), 165.2 (C=O), 168.6 (C=O); HRMS: Calculated for C42H41N3O8Na: 738.2791; found 
738.2777 [M+Na]+. 
 
8.1.12.2. (9H-Fluoren-9-yl)methyl (1-((2-methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-
trimethoxyphenyl)azetidin-2-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate 
(11d) was prepared from 11 and Fmoc-protected valine following the general method 
above and was isolated as a brown oil in 51% yield; IR (NaCl film) νmax: 1748 cm-1 (β-
lactam -C=O), 1686 cm-1 (C=O); 1H NMR (400 MHz, CDCl3) δ 1.01-1.04 (m, 6H, 2 × 
CH3), 2.20-2.28 (m, 1H, CH), 3.75-3.88 (m, 12H, 4 × OCH3), 4.18 (m, 2H), 4.24 (m, 1H, 
CH), 4.43-4.48 (m, 2H), 4.92 (s, 1H, CH), 5.49 (d, 1H, J=8.6 Hz), 6.66 (s, 2H, ArH), 6.81 
(s, 1H, ArH), 6.92-6.94 (m, 1H, ArH), 7.16-7.18 (m, 1H, ArH), 7.31-7.45 (m, 9H, ArH), 
7.62-7.63 (m, 2H, ArH), 7.77 (m, 2H, ArH), 8.23 (s, 1H, ArH), 8.54 (m, 1H, ArH); 13C 
NMR (100 MHz, CDCl3) δ 17.5 (CH3), 18.8 (CH3), 30.7 (CH), 46.7 (CH), 55.1 (OCH3), 
55.5 (OCH3), 55.6 (OCH3), 55.7 (OCH3), 60.5 (OCH3), 61.0 (OCH3), 63.3 (C3), 63.6 
(C3), 64.3 (C4), 64.4 (C4), 66.8 (CH2), 94.4 (CH, Ar), 94.4 (CH, Ar), 94.5 (CH, Ar), 110.1 
(CH, Ar), 110.3 (CH, Ar), 111.3 (CH, Ar), 111.4 (CH, Ar), 115.8 (CH, Ar), 116.3 (CH, 
Ar), 117.9 (CH, Ar), 119.6 (CH, Ar), 120.8 (CH, Ar), 120.9 (CH, Ar), 124.6 (CH, Ar), 
126.2 (CH, Ar), 126.6 (CH, Ar), 126.8 (CH, Ar), 127.0 (CH, Ar), 127.1 (CH, Ar), 127.2 
(CH, Ar), 127.3 (CH, Ar), 127.4 (CH, Ar), 128.5 (CH, Ar), 128.6 (CH, Ar), 129.4 (CH, 
Ar), 133.2 (C, Ar), 133.4 (C, Ar), 133.9 (C, Ar), 134.1 (C, Ar), 134.4 (C, Ar), 136.1 (C, 
Ar), 140.8 (C, Ar), 143.2 (C, Ar), 143.3 (C, Ar), 147.8 (C, Ar), 153.0 (C, Ar), 156.0 (C, 
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Ar), 165.3 (C=O), 172.1 (C=O); HRMS: Calculated for C45H45N3O8Na: 778.3104; found 
778.3107 [M+Na]+. 
 
8.1.13. General methods for removal of Fmoc protecting group for preparation of 
10g-10j and 11i-11o 
General method 1: To the Fmoc-amino acid amide (2.1 mmol) at room temperature in 
CHCl3 (55 mL) was added piperidine (2 mL). The mixture was stirred and monitored 
until complete on TLC. The solvent was evaporated under reduced pressure. The product 
was isolated by flash column chromatography (dichloromethane: methanol gradient, 
100:0 to 90:10). 
 
General method 2: To the Fmoc-amino acid amide dissolved in CH2Cl2 (minimum 
volume, 1-2 mL) was added 1-octanethiol (10 equiv.) and TBAF (2 equiv.). The mixture 
was stirred at room temperature until complete on TLC, typically within 10 minutes. The 
solvent was evaporated under reduced pressure and product was isolated by flash column 
chromatography (dichloromethane: methanol gradient, 100:0 to 90:10). 
 
8.1.13.1. 2-Amino-N-(2-methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-
trimethoxyphenyl)azetidin-2-yl)phenyl)-3-methylbutanamide (11l) was prepared from 
11d by general method 2 and was obtained as a yellow oil in 57% yield; IR (NaCl film) 
νmax: 3380.25 cm-1 (NH2), 1747.97 cm-1 (β-lactam -C=O), 1676.35 cm-1 (-C=O); 1H NMR 
(400 MHz, CDCl3) δ 0.88 (d, 3H, J=7 Hz), 1.05 (d, 3H, J=7 Hz), 2.35 (m, 1H), 3.75-3.77 
(m, 10H), 3.92 (s, 3H), 4.29-4.37 (m, 1H), 4.78-4.92 (m, 1H), 6.65 (s, 2H), 6.79 (s, 1H), 
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6.93 (m, 1H), 7.13 (m, 1H), 7.29-7.36 (m, 5H), 8.66 (d, 1H, J=13 Hz), 10.00 (d, 1H, J=13 
Hz); 13C NMR (100 MHz, CDCl3) δ 19.2 (CH3), 19.3 (CH3), 30.4 (CH), 30.5 (CH), 55.1, 
55.5 (OCH3), 55.6 (OCH3), 55.7 (OCH3), 60.4 (OCH3), 60.5 (OCH3), 63.4 (C3), 63.6 
(C3), 64.2 (C4), 64.3 (C4), 94.4 (CH, Ar), 94.5 (CH, Ar), 110.0 (CH, Ar), 110.2 (CH, Ar), 
110.3 (CH, Ar), 111.0 (CH, Ar), 115.8 (CH, Ar), 117.5 (CH, Ar), 117.9 (CH, Ar), 120.0 
(CH, Ar), 120.1 (CH, Ar), 126.9 (CH, Ar), 127.0 (CH, Ar), 127.3 (CH, Ar), 127.4 (CH, 
Ar), 127.5 (CH, Ar), 127.6 (CH, Ar), 128.3 (CH, Ar), 129.3 (CH, Ar), 129.4 (CH, Ar), 
133.3 (C, Ar), 133.4 (C, Ar), 133.9 (C, Ar), 134.2 (C, Ar), 134.3 (C, Ar), 134.5 (C, Ar), 
136.7 (C, Ar), 147.1 (C, Ar), 148.0 (C, Ar), 148.1 (C, Ar), 153.0 (C, Ar), 165.3 (C=O), 
165.3 (C=O), 172.3 (C=O); HRMS: Calculated for C30H36N3O6: 534.2604; found 
534.2584 [M+H]+. 
 
8.1.14. Synthesis of 7h, 10k-10m and 11p-11r  
The carboxybenzyl or benzyl protected compound 7e, 10e, 10f, 10j, 11h, 11n or 11o (2 
mmol) was dissolved in ethanol: ethyl acetate (50 mL; 1:1 mixture) and hydrogenated 
over 1.2g of 10% palladium on carbon until complete on TLC, typically less than 2 hours. 
The catalyst was filtered, the solvent was evaporated under reduced pressure and the 
product was isolated by flash column chromatography (dichloromethane: methanol 
gradient, 100:0 to 90:10). 
8.1.14.1. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-
yl)phenyl 2-aminopropanoate (7h) was prepared from compound 7e following the 
procedure above in 58% yield. IR (NaCl film) νmax: 1748.1 (β-lactam -C=O); 1H NMR 
(400 MHz, CDCl3) δ 1.54 - 1.56 (m, 3H, CH3), 3.76-3.92 (m, 12H, 4 × OCH3), 4.30-4.32 
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(m, 1H, H3), 4.83-4.88 (m, 1H, H4), 6.62 - 6.64 (m, 2H, ArH), 6.88 - 6.95 (m, 1H, ArH), 
7.01-7.04 (m, 1H, ArH), 7.14-7.15 (m, 1H, ArH), 7.34-7.41 (m, 5H, ArH); 13C NMR 
(100 MHz, CDCl3) δ 20.6 (CH3), 56.0 (OCH3), 56.1 (OCH3), 60.9 (OCH3), 63.5 (C3), 
63.8 (C3), 64.9 (C4), 65.0 (C4), 94.8 (CH, Ar), 94.9 (CH, Ar), 111.1 (CH, Ar), 112.1 (CH, 
Ar), 113.0 (CH, Ar), 117.9 (CH, Ar), 120.6 (CH, Ar), 124.5 (CH, Ar), 127.4 (CH, Ar), 
127.9 (CH, Ar), 128.0 (CH, Ar), 129.0 (CH, Ar), 129.1 (CH, Ar), 129.9 (CH, Ar), 130.5 
(CH, Ar), 133.7 (C, Ar), 134.4 (C, Ar), 134.5 (C, Ar), 134.8 (C, Ar), 140.3 (C, Ar), 146.4 
(C, Ar), 146.9 (C, Ar), 153.5 (C, Ar), 153.6 (C, Ar), 165.6 (C=O); HRMS: Calculated for 
C28H31N2O7: 507.2131; found 507.2152 [M+H]
+. 
 
8.1.14.2. 2-Amino-N-(4-(2-(4-methoxyphenyl)-4-oxo-1-(3,4,5-
trimethoxyphenyl)azetidin-3-yl)phenyl)-3-phenylpropanamide (10k) was prepared 
from 10e following the procedure above as a yellow oil in 51% yield; IR (NaCl film) 
νmax: 1742 cm-1 (β-lactam -C=O), 1684 cm-1 (-C=O); 1H NMR (400 MHz, CDCl3) δ 2.82-
2.88 (m, 1H, CH2), 3.35-3.39 (m, 1H, CH2), 3.79-3.85 (m, 13H, 4 × OCH3, CH), 4.26 (s, 
1H), 4.84 (d, 1H, J=2.5 Hz), 6.62 (s, 2H), 6.97 (d, 3H, J=8.5 Hz), 7.25-7.39 (m, 10H), 
9.52 (s, 1H, NH); 13C NMR (100 MHz, CDCl3) δ 40.0 (CH2), 54.4 (OCH3), 55.6 (OCH3), 
56.2 (CH), 58.8 (CH), 60.5 (OCH3), 63.5 (C3), 64.2 (C4), 94.4 (CH, Ar), 114.2 (CH, Ar), 
119.7 (CH, Ar), 124.1 (CH, Ar), 126.6 (CH, Ar), 126.9 (CH, Ar), 127.6 (CH, Ar), 127.8 
(CH, Ar), 128.1 (CH, Ar), 128.2 (CH, Ar), 128.3 (CH, Ar), 128.4 (CH, Ar), 128.7 (CH, 
Ar), 128.9 (CH, Ar), 129.3 (CH, Ar), 129.9 (CH, Ar), 133.2 (C, Ar), 133.9 (C, Ar), 136.2 
(C, Ar), 136.9 (C, Ar), 153.0 (C, Ar), 159.4 (C, Ar), 159.5 (C, Ar), 164.7 (C=O), 165.3 
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(C=O), 171.7 (C=O), 174.0 (C=O); HRMS: Calculated for C34H36N3O6: 582.2604; found 
582.2613 [M+H]+. 
 
8.2. Solubility measurement. Solubility testing was carried out on selected samples 7, 
7a, 8, 8a, 9, 9a, 10, 10g, 10i, 10k, 10l, 11, 11j, 11k, 11l, 11p and 11q as follows: An 
amount of compound approximately equal to 5 mg was accurately weighed and 
suspended in a corresponding amount of distilled water in a vial (Wheaton sample vials 
with rubber lined caps) to give a concentration of 1 mg/mL. This suspension was placed 
on a shaking plate (IKA® MTS 2/4 digital) and agitated at 300 shakes/minute for 24 
hours. After 24 hours, the vials were removed from the shaking plate. The 
solution/suspensions were filtered and the filtrate was assayed by HPLC using the 
conditions described above for purity testing to determine the amount of compound in 
solution. 
 
8.3. Biochemical Methods 
8.3.1. Antiproliferative studies. All assays were performed in triplicate for the 
determination of mean values reported. Compounds were assayed as the free bases 
isolated from reaction. The human breast tumour cell line MCF-7 was cultured in Eagles 
minimum essential medium in a 95% O2/5% CO2 atmosphere with 10% fetal bovine 
serum, 2 mM L-glutamine and 100 µg/mL penicillin/streptomycin. The medium was 
supplemented with 1% non-essential amino acids. Cells were trypsinised and seeded at a 
density of 2.5 × 104 cells/mL in a 96-well plate and incubated at 37 oC, 95%O2/5% CO2 
atmosphere for 24 h. After this time they were treated with 2 µL volumes of test 
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compound which had been pre-prepared as stock solutions in ethanol to furnish the 
concentration range of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control 
wells contained the equivalent volume of the vehicle ethanol (1% v/v). The culture 
medium was then removed and the cells washed with 100 µL phosphate buffered saline 
(PBS) and 50 µL MTT (1 mg/mL solution in PBS) added. Cells were incubated for 2 h in 
darkness at 37 oC. At this point solubilization was begun through the addition of 200 µL 
DMSO and the cells maintained at room temperature in darkness for 20 min to ensure 
thorough colour diffusion before reading the absorbance. The absorbance value of control 
cells (no added compound) was set to 100% cell viability and from this graphs of 
absorbance versus cell density per well were prepared to assess cell viability and from 
these, graphs of percentage cell viability versus concentration of compound added were 
drawn. 
 
8.3.2. Tubulin polymerisation assay. The effect of selected compounds on the 
polymerisation of purified bovine brain tubulin was determined spectrophotometrically 
by monitoring the change in turbidity. Lyophilised tubulin (Cytoskeleton, Denver, CO) 
was re-suspended in ice cold G-PEM buffer (80 mM PIPES pH 6.9, 0.5 mM MgCl2, 
1mM EGTA, 1 mM GTP, 10.2% (v/v) glycerol) and added to wells on a half volume 96 
well plate containing the designated concentration of drug or vehicle. Samples were 
mixed well and tubulin assembly was monitored at A340 nm at 30 sec intervals for 60 min 
at 37oC in a Spectramax 340PC spectrophotometer (Molecular Devices). IC50 values were 
calculated at 30 mins using GraphPad Prism software (GraphPad Software, Inc.). 
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8.3.3. Immunofluorescence and confocal microscopy. For immunofluorescence, MCF-
7 cells were seeded at 1 × 105 per well on BD falcon four well chamber glass slides (BD 
Biosciences, San Jose, USA. Cells were treated with vehicle [1% ethanol (v/v)]; 2, 8a, 
9a, 10k, [100 nM] or 11l [1 µM] for 16 h. Following treatment, cells were washed gently 
in PBS, fixed for 30 min in methanol at -20 oC. Following washes in PBST (PBS and 
0.1% Triton-X-100), cells were blocked in 5% BSA diluted in PBST (blocking buffer). 
Cells were then incubated with mouse anti-tubulin (DM1A (Merck Chemicals Ltd); 1:20 
for 1 h at room temperature. Following washes in PBST cells were incubated with 
fluorescein isothiocyanate (FITC) conjugated rabbit anti-mouse (Dakocytomation, UK); 
1:100 for 1 h at room temperature. Following washes in PBST, the cells were mounted in 
Ultra Cruz Mounting Media (Santa Cruz Biotechnology, Santa Cruz, CA) containing 4,6-
diamino-2-phenolindol dihydrochloride (DAPI). Confocal images were captured using 
the OLYMPUS 1X81 microscope coupled with OLYMPUS FLUOVIEW Ver 1.5 
software. All images in each experiment were collected on the same day using identical 
parameters. 
 
8.3.4. Determination of DNA content by flow cytometry. MCF-7 cells were seeded at 
1 × 105 cells/cm3. After 24 h, cells were treated with vehicle [1% ethanol (v/v)]; 2, 7a, 8a, 
9a, 10k, [100 nM] or 11l [1 µM] for 48 h. Cells were harvested by centrifugation at 800 × 
g for 10 min. Cell pellets were re-suspended in PBS and fixed in 70% ethanol: PBS 
overnight at -20 oC. Following centrifugation cell pellets were re-suspended in PBS 
supplemented with 0.5 mg/ml RNase and 0.15 mg/ml propidium iodide (PI). Following a 
30 min incubation at 37oC in the dark the PI fluorescence was measured on a linear scale 
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using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). The amount of 
PI fluorescence is directly proportional to the amount of DNA present in each cell. The 
relative content of DNA indicates the distribution of a population of cells throughout the 
cell cycle. For example, cells in G0G1 are diploid and have a DNA content of 2N. Cells 
with the G2M phases have a DNA content of 4N, while cells in S-phase have a DNA 
content between 2N and 4N. Apoptotic cells are sub-diploid (<2N). Data collection was 
gated to exclude cell debris and cell aggregates. At least 10,000 cells were analysed per 
sample. All data were recorded and analysed using the CellQuest software (Becton 
Dickinson).  
 
8.4. Computational Procedures. For ligand preparation, all compounds were built in 
Molecular Operating Environment 2011.10 (MOE 2011.10) [38] and energy minimised. 
Conformers of these compounds were generated in MOE 2011.10 using the conformation 
search option. The stochastic method was chosen with an iteration limit of 100. All other 
parameters were remained unchanged. For the receptor preparation, the PDB entry 1SA0 
was downloaded from the Protein Data Bank (PDB) [33]. All waters were retained in 
both isoforms. Addition and optimisation of hydrogen positions for these waters was 
carried out using MOE 2011.10 ensuring all other atom positions remained fixed. Using 
the reported X-ray structure of tubulin co-crystallised with a colchicine derivative, 
DAMA-colchicine (PDB entry-1SA0), possible binding orientations of the β-lactam 
ligands were probed with the docking program MOE 2011.10. Docking was carried out 
using MOE 2011.10, using the DAMA-colchicine to identity the binding site. Each 
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conformation was subsequently docked using the Triangle Matcher placement 
methodology setting. All the default parameters remained unchanged.  
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Table Captions 
Table 1. Antiproliferative activities and physiochemical properties of β-lactam phosphate 
esters 
aIC50 values are half maximal inhibitory concentrations required to inhibit the growth of 
MCF-7. Values represent the mean ± S.E.M for at least three independent experiments 
performed in triplicate. The IC50 value obtained for 2 in this assay was 5 nM for MCF-7 
and is in good agreement with the reported values for 2 using the MTT assay on human 
MCF-7 breast cancer cell line [31, 39, 40]. 
bCLogP value calculated using ChemDraw Ultra and refers to CLogPoct/water  
cSolubility value taken as the maximum value from n=3, where each sample was assayed 
three times 
dSolubility is below the level of detection of the assay 
 
Table 2. Antiproliferative activity and solubility of β-lactam amino acid amides derived 
from 10 
aIC50 values are half maximal inhibitory concentrations required to inhibit the growth of 
MCF-7. Values represent the mean ± S.E.M for at least three independent experiments 
performed in triplicate 
bCLogP value calculated using ChemDraw Ultra and refers to CLogPoct/water 
cSolubility value taken as the maximum value from n=3, where each sample was assayed 
three times 
dSolubility is below the level of detection of the assay; nd=not determined 
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Table 3. Antiproliferative activity and solubility of β-lactam amino acid amides derived 
from 11 
aIC50 values are half maximal inhibitory concentrations required to inhibit the growth of 
MCF-7. Values represent the mean ± S.E.M for at least three independent experiments 
performed in triplicate.  
bCLogP value calculated using ChemDraw Ultra and refers to CLogPoct/water 
cSolubility value taken as the maximum value from n=3, where each sample was assayed 
three times 
dSolubility is below the level of detection of the assay; nd= not determined 
eIn murine 26 colon cells [21] 
fHuman plasma, pH 7.2-7.5 [21] 
 
Figure captions 
Figure 1. Phosphate prodrugs of tubulin-binding agents NAC, CA-4, CA-1 and 
phenstatin 
 
Figure 2. Amino-acid prodrugs of amino analogues of CA-4 and CA-2 
 
Figure 3. Antiproliferative β-lactams chosen for prodrug development. One 
enantiomer is illustrated. 
 
Figure 4. Effects of compounds 7, 7a, 9 and 9a on the inhibition of tubulin 
polymerisation.  
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Effects of compounds 7, 7a, 9 and 9a (10 µM) on in vitro tubulin polymerisation. 
Purified bovine tubulin and GTP were mixed in a 96-well plate. The reaction was started 
by warming the solution from 4 oC to 37oC. Ethanol (1%v/v) was used as a vehicle 
control. The effect on tubulin assembly was monitored in a Spectramax 340PC 
spectrophotometer at 340nm at 30 second intervals for 60 minutes at 37 oC. The graph 
shows one representative experiment. Each experiment was performed in triplicate. 
 
Figure 5. Effects of compound 11l on the inhibition of tubulin polymerisation.  
Dose-response effect of compound 11l on in vitro tubulin polymerisation. Purified bovine 
tubulin and GTP were mixed in a 96-well plate. The reaction was started by warming the 
solution from 4 oC to 37oC. Ethanol (1%v/v) was used as a vehicle control. The effect on 
tubulin assembly was monitored in a Spectramax 340PC spectrophotometer at 340nm at 
30 second intervals for 60 minutes at 37 oC. The graph shows one representative 
experiment. Each experiment was performed in triplicate. 
 
Figure 6. Compound 2 and β-lactams 8a and 9a depolymerise the microtubule 
network of MCF-7 cells resulting in mitotic catastrophe. MCF-7 cells were treated 
with vehicle control (1% ethanol (v/v), A+E), or compound 2 (B+F), 8a (C+G) or 9a 
(D+H) (all 100 nM) for 16 h. Cells were fixed in methanol and stained with α-tubulin 
mAbs (green) and counterstained with DAPI (blue). Images were captured by confocal 
microscopy coupled with OLYMPUS FLUOVIEW software. Bar equal to 40 µm. 
Representative confocal micrographs of three separate experiments are shown. 
 
 45 
 
Figure 7. Compound 2 and β-lactams 10k and 11l depolymerise the microtubule 
network of MCF-7 cells resulting in mitotic catastrophe. MCF-7 cells were treated 
with vehicle control (1% ethanol (v/v), A+D), compound 10k (B+E; 100 nM) or 11l 
(C,+F; 1 µM) for 16 h. Cells were fixed in methanol and stained with α-tubulin mAbs 
(green) and counterstained with DAPI (blue). Images were captured by confocal 
microscopy coupled with OLYMPUS FLUOVIEW software. Bar equal to 20 µm. 
Representative confocal micrographs of three separate experiments are shown. 
 
Figure 8. Effects of 2 and β-lactams 7, 8, 9, 7a, 8a, 9a, 10k, 11l on the cell cycle. 
Percentages of cells in (A) sub-G1 and (B) G2/M phase after treatment with β-
lactams. MCF-7 cells were untreated (U), treated with vehicle control (V, 1% ethanol 
(v/v)), or compound 2, 7, 8, 9, 7a, 8a, 9a, 10k (100 nM) or 11l (1 µM) for 48 h. Values 
represent the mean ± SEM for at least three independent experiments. Using one –way 
anova followed by Bonferroni's Multiple Comparison Test, there is no statistical 
difference between all β-lactam compounds for percentage of cells in sub-G1. G2/M 
p<0.001 for all compounds compared to vehicle with no statistical difference between 
parent compounds and derivatives. 
 
Figure 9. 2D representation of the binding interactions of (A) 10 and (B) 10k with the 
colchicine binding site of tubulin. 
 
Figure 10. 2D representation of the binding interactions of (A) 11 and (B) 11l with the 
colchicine binding site of tubulin. 
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Scheme Captions 
Scheme 1. Preparation of β-lactam phosphate esters 7a, 8a, 9aa 
aReagents and conditions: (a) Dibenzyl phosphite, dimethyl phosphite, or diethyl 
phosphite, DIPEA, DMAP, CCl4, CH3CN (b) Pd/C, H2, EtOH:EtOAc (1:1) (c) (i) 
BrSi(CH3)3, CH2Cl2 (ii) Na2S2O3. (Bn = -CH2C6H5) 
*Only one enantiomer is illustrated  
 
Scheme 2. Synthesis of β-lactams 7e-7la 
aReagents and conditions: (a) DCC, DMAP (b) H2, Pd, EtOh, EtOAc (c) Et3N, 
C6H5CH2COCl, CH2Cl2 (d) BrCH2CH2Br, (nBu)4NHSO4, NaOH; (e) Et3N, 
C6H5CH2COCl, CH2Cl2; (f) MeNH2 
 
Scheme 3. Preparation of β-lactams 10a-10j and 11a-11oa 
aReagents and conditions: (a) N-protected L-amino acid, anhydrous DMF, DCC (polymer 
supported), HOBt.H2O, stirring, rt; (b) TBAF, 1-octanethiol, CH2Cl2, rt 
 
Scheme 4. Preparation of β-lactams 10k-10m and 11p-11ra 
aReagents and conditions: (a) H2, Pd/C, EtOAc: EtOH 1:1, rt 
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Table 1.  
 
 
 IC50 MCF-7 
(nM)a 
CLogPb Solubility 
(mg/mL)c 
 R1= R2=    
7 H C6H5 9.6 ± 2.6[4] 3.14 0
d 
7a P(O)(OH)2 C6H5 71 ± 35 2.09 0.30 
8 H 
 
7.0 ± 2.0[5] 2.79 0d 
8a P(O)(OH)2 
 
20 ± 8 1.74 0.45 
9 H p-C6H4OH 0.8 ± 0.4[4] 2.47 0
d 
9a P(O)(OH)2 p-C6H4OH 22 ± 11 1.43 0.14 
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Table 2.  
 Structure
 
Amino acid IC50 (nM)a CLogPb Solubility 
(mg/mL)c 
 R=     
10g H Gly 91 ± 10 1.99 0.06 
10h CH3 Ala 35 ± 20 2.30 nd 
10i (CH2)4NH2 Lys 690  ± 700 2.00 0
d 
10k CH2C6H5 Phe 27 ± 0.3 3.71 0.14 
10l CH(CH3)2 Val 50 ± 20 3.22 0.004 
10m CH2OH Ser 860 ± 300 1.13 nd 
10 Parent compound   50 ± 20 [4] 2.65 0 
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Table 3.  
 Structure
 
Amino acid IC50 MCF-7 
(nM)a 
CLogPb Solubility 
(mg/mL)c 
 R=     
11i H Gly 1100 ± 900 1.55 nd 
11j CH3 Ala 760 ± 230 1.86 0.37 
11k CH2C6H5 Phe 1130 ± 500 3.28 0
d 
11l CH(CH3)2 Val 460 ± 200 2.79 0.11 
11m (CH2)4NH2 Lys 9800 ± 2000 1.56 nd 
11p CH(CH3)C2H5 Ile 1100 ± 900 3.32 0.11 
11q CH2OH Ser 780 ± 200 0.70 0.20 
11r CH2C6H4OH Tyr 740 ± 60 2.61 nd 
11 Parent compound (Figure 3)  650 ± 10 [4] 3.00 0d 
5a 
 
Ser 37 e 0.87 0.11f 
 
 
 
 50 
 
 
 
Figure 1.  
 
Figure 2.  
 51 
 
 
 
 
Figure 3.  
 52 
 
 
Figure 4.  
 
 53 
 
 
Figure 5.  
 54 
 
 
 
Figure 6.  
 55 
 
 
 
Figure 7.  
 56 
 
 
 
Figure 8.  
 
 57 
 
 
A.  
 
A 
B 
C 
 58 
 
B. 
 
 
Figure 9.  
 
B 
A 
C 
 59 
 
 
A. 
 
A 
B 
C 
 60 
 
B. 
 
Figure 10.  
 
 
A 
B 
C 
 61 
 
Schemes 
Scheme 1.  
 
 
 
 62 
 
Scheme 2.  
 
 
 63 
 
Scheme 3.  
 64 
 
Scheme 4.  
 
 
 
